Table 5 Response to first-line chemotherapy and survival in patients with CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma
| Â | CD20-negative DLBCL(n = 21) | CD20-positive DLBCL (n = 63) | P |
|---|---|---|---|
Response | Â | Â | Â |
Assessable, n | 21 | 63 | Â |
CR | 9 (42.9%) | 52(82.5%) | 0.001 |
No CR | 12(57.1%) | 11(17.5%) | Â |
Survival | Â | Â | Â |
3-years PFS | 30.5% | 52% | 0.008 |
Median PFS, months (range) | 6(1-117) | 39(2-121) | Â |
3-years OS | 35% | 74.1 % | 0.008 |
Median OS, months (range) | 23(3-117) | Not reached(2-121) | Â |